ALTTO Test of Dual HER2 Blockade Finds Single Agent — Trastuzumab — Remains the Gold Standard
Mayo ClinicCHICAGO — June 2, 2014 — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology (ASCO).